Seeking Alpha
View as an RSS Feed

Brad Kenagy  

View Brad Kenagy's Comments BY TICKER:
Latest comments  |  Highest rated
  • Substantial Upside Potential With This Unique ETF [View article]
    Well said!
    May 22, 2015. 03:36 PM | Likes Like |Link to Comment
  • Substantial Upside Potential With This Unique ETF [View article]
    It was a good discussion, which showed the advantages and disadvantages of both BBC and SBIO. In addition, significant value was provided to readers of this article because BioShares themselves commented on this article added to the discussion. Thank you Joseph for the article and the exchanges we had.
    May 22, 2015. 03:23 PM | 1 Like Like |Link to Comment
  • Rising Rates Portfolio: 2015 Edition [View article]
    Thank you for the comment. I don't see how you could have alot of money on PCY, as it is within a couple percent of an all-time high? Unless you frequently trade it, I don't see it.
    May 21, 2015. 03:21 PM | Likes Like |Link to Comment
  • Substantial Upside Potential With This Unique ETF [View article]
    Thank you Paul for the valuable information on BBC and BBP.
    May 20, 2015. 04:30 PM | Likes Like |Link to Comment
  • Substantial Upside Potential With This Unique ETF [View article]
    Here is some more information to shed light on the issue of comparison. I looked at the holdings of BBC and compared them to all other biotech ETFs to see the common holdings in each: PBE, ARKG, SBIO, IBB, XBI, FBT, BBH and the data I found is below. As you can see XBI, and IBB have the largest number of common holdings, however those funds focus on large cap biotech as well. Moving down the list you see SBIO, which focuses exclusively on small/lower midcap [$5 billion max] biotech just like BBC does! SBIO is clearly the superior choice as a comparison fund. Especially when you see that PBE and ARKG have a limited number of common holdings.

    As I stated Before in my above post and this post further reinforces that SBIO is the clear winner in comparison to BBC.

    XBI Common Holdings: 47, Common as % Of Total XBI Holdings 47.47%
    IBB Common Holdings: 58, Common as % Of Total IBB Holdings 39.73%
    SBIO Common Holdings: 28, Common as % Of Total SBIO Holdings 38.89%
    FBT Common Holdings: 5, Common as % Of Total FBT Holdings 16.67%
    PBE Common Holdings: 5, Common as % Of Total PBE Holdings 16.67%
    ARKG Common Holdings: 8, Common as % Of Total ARKG Holdings 16.33%
    BBH Common Holdings: 3, Common as % Of Total BBH Holdings 11.54%

    Disclosure: Long SBIO
    May 20, 2015. 01:09 PM | Likes Like |Link to Comment
  • Substantial Upside Potential With This Unique ETF [View article]
    Great article, and description of BBC. However I believe you should have included SBIO in your comparison of competing funds. Like BBC, SBIO targets those companies with products in clinical trials specifically, phase 2 & phase 3 trials. In addition, SBIO screens out those companies that do not have enough cash on hand to last for 2 years, where BBC does not screen for balance sheet liquidity.

    Even ETF.com says: "You will find a new competing fund with a similar thesis in BBC" http://www.etf.com/SBIO

    Each fund has similar:

    -Market cap requirements
    -Both have companies with phase 2 and phase 3 candidates
    -Each has Similar daily turnover requirements

    However!

    SBIO:

    -SBIO screens for balance sheet liquidity and includes only those companies with an estimated amount of cash that is enough cash for two years.
    -SBIO has returned just over 30% ytd, while BBC has returned just over 22%
    -SBIO Charges less, 0.50% management fee vs 0.85% for BBC
    -SBIO Has More Volume
    -SBIO Trades with tighter spreads than BBC
    -SBIO Has more assets than BBC even though it has been around for less time than BBC.

    It is easy to see why you left SBIO out... In my opinion it is a superior fund by far than BBC.

    Disclosure: I am long SBIO.
    May 20, 2015. 10:28 AM | 4 Likes Like |Link to Comment
  • ILS, Cat Bonds And Reinsurance, An Asset Class To Offset A Crisis [View article]
    Is there someplace to find individual cat bonds, or related securities to purchase? Or is there a company that buys them?
    May 19, 2015. 01:29 PM | Likes Like |Link to Comment
  • The Drawbacks Of Apple's Cash Hoard Are Starting To Show [View article]
    Steven, Thank you for the comment, I completely agree that Tax reform is needed. However, I believe that if tax reform is enacted there will most likely be clause that says the money brought back has to be used for New Plants, R&D etc, and not to be used for shareholder returns through dividends or buybacks.
    May 19, 2015. 01:20 PM | Likes Like |Link to Comment
  • Carl Icahn Is Wrong, Apple Is Not Worth $240 Today [View article]
    Good article, I wrote a very similar article in February about his previous price target of $216 being unrealistic.

    http://seekingalpha.co...

    My Main points were:

    -He Modeled for significantly higher buybacks than Apple has done or is doing.
    -He Modeled for dividends not to increase at all during the next 3 years.
    -He also assumed that debt would be flat over the next three years as well.
    May 19, 2015. 10:16 AM | 3 Likes Like |Link to Comment
  • Public Storage: Safety At A Premium Price [View article]
    Thank you for the comment, the preferreds are interesting for those investors looking for even more safety.
    May 19, 2015. 10:03 AM | Likes Like |Link to Comment
  • Icahn hikes Apple target to $240, sees FY16 EPS of $12 [View news story]
    Apple cannot currently access its large foreign cash hoard unless they want to pay a significant amount in taxes. Currently they have just over 88% of their cash "stuck" overseas leaving roughly $22.5 billion at end of MRQ + $8 billion from recent bond offering to use for capital returns in addition to free cash flows. With Apple needing roughly an average of $11 billion Per quarter over the next 8 quarters [Length of Capital return program], to fund its capital return program they will continue to have to issue large amounts of debt.

    http://seekingalpha.co...
    May 18, 2015. 01:43 PM | 2 Likes Like |Link to Comment
  • Gilead Sciences: The Best GARP Stock In The S&P 500 [View article]
    I wrote a article focusing on the opposite of GARP, my newly coined SAPP "Safety At a Premium Price", which I search for companies that are considered "Safe" however they are trading at a valuation higher than the average S&P 500 stock, and have lower expected growth.

    http://seekingalpha.co...
    May 18, 2015. 01:33 PM | Likes Like |Link to Comment
  • Gilead Sciences: The Best GARP Stock In The S&P 500 [View article]
    Thank you for the comment. I am glad I decided to screen for GARP stocks, because with the positive valuation and catalysts GILD is an attractive opportunity, which is why I decided to initiate a position.
    May 18, 2015. 01:31 PM | Likes Like |Link to Comment
  • Public Storage: Safety At A Premium Price [View article]
    Thank you for the comment. Like I said PSA is a great company, however the price based on the expected future growth is expensive.
    May 18, 2015. 12:04 PM | Likes Like |Link to Comment
  • Gilead Sciences: The Best GARP Stock In The S&P 500 [View article]
    With Solvaldi receiving a higher price in Japan than estimated, andlikely approval of Harvoni sometime around July in Japan, it is easy to see there is still a ton of Upside in GILD.

    http://seekingalpha.co...
    May 15, 2015. 11:25 PM | 1 Like Like |Link to Comment
COMMENTS STATS
1,943 Comments
1,056 Likes